Canaccord Adams Downgrades Arena Pharmaceuticals (ARNA) to Sell; Drops Price Target on High Clinical Risks
Tweet Send to a Friend
Canaccord Adams downgrades Arena Pharmaceuticals (Nasdaq: ARNA) to Sell. Price target lowered from $4 to $2.50.
Canaccord analyst says, "First ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "First ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
